Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (BDTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BDTX · as of Sep 30, 2025
Ownership Breakdown
90
Institutional Holders
▼ 3 vs Q2
$146.97M
Total Inst. Value
▲ $51.21M vs Q2
57.30M
Shares Outstanding
freeFloat 80.33%
38.78M
13F Shares Held
▲ 164,219 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BDTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 10.74M | 18.91% | 18.91% | $40.72B | Nov 14, 2025 | ▲ 232.0K |
VESTAL POINT CAPITAL, LP biological products, (no diagnostic substances) | 5.55M | 9.77% | 9.77% | $21.03B | Nov 14, 2025 | ▼ 50.0K |
NEA MANAGEMENT COMPANY, LLC biological products, (no diagnostic substances) | 4.45M | 7.83% | 7.83% | $16.86B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.19M | 3.85% | 3.85% | $8.30B | Nov 7, 2025 | ▲ 85.8K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.07M | 3.64% | 3.64% | $7.85B | Nov 14, 2025 | — held |
MARSHALL WACE, LLP biological products, (no diagnostic substances) | 1.30M | 2.29% | 2.29% | $4.92B | Nov 13, 2025 | ▲ 561.3K |
SIREN, L.L.C. biological products, (no diagnostic substances) | 1.05M | 1.84% | 1.84% | $3.97B | Nov 13, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.03M | 1.81% | 1.81% | $3.90B | Nov 12, 2025 | ▼ 62.8K |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP biological products, (no diagnostic substances) | 896.9K | 1.58% | 1.58% | $3.40B | Nov 13, 2025 | ▲ 758.7K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 850.3K | 1.50% | 1.50% | $3.22B | Nov 14, 2025 | ▼ 94.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+4.13M shares8
New Positions
first time holders9
Decreased
−574.1K shares0
Sold Out
fully exitedNet shares change (top 50)
+3.55M
+4.13M / −574.1K
Net new holders
+25
8 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BDTX insider trading · insider activity
Source: SEC Form 4
7
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Behbahani Ali director | Mar 20, 2026 | Award | 6,919 | $2.15 | $14.9K | 93.6K | Form 4 ↗ |
Raman Prakash director | Mar 20, 2026 | Award | 6,105 | $2.15 | $13.1K | 37.1K | Form 4 ↗ |
Jones Erika SEE REMARKS | Jan 21, 2026 | Award | 200,000 | $2.57 | $514.0K | 200.0K | Form 4 ↗ |
Hatzis-Schoch Brent SEE REMARKS | Jan 21, 2026 | Award | 250,000 | $2.57 | $642.5K | 250.0K | Form 4 ↗ |
Buck Elizabeth CHIEF SCIENTIFIC OFFICER | Jan 21, 2026 | Award | 250,000 | $2.57 | $642.5K | 250.0K | Form 4 ↗ |
Yurasov Sergey CHIEF MEDICAL OFFICER | Jan 21, 2026 | Award | 250,000 | $2.57 | $642.5K | 250.0K | Form 4 ↗ |
Velleca Mark A. PRESIDENT & CEO | Jan 21, 2026 | Award | 600,000 | $2.57 | $1.54M | 600.0K | Form 4 ↗ |
Behbahani Ali director | Dec 12, 2025 | Award | 5,208 | $2.76 | $14.4K | 86.6K | Form 4 ↗ |
Raman Prakash director | Dec 12, 2025 | Award | 4,665 | $2.76 | $12.9K | 31.0K | Form 4 ↗ |
Behbahani Ali director | Sep 19, 2025 | Award | 4,291 | $3.35 | $14.4K | 81.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Black Diamond Therapeutics, Inc. (BDTX) is primarily owned by institutional investors, who hold approximately 67.7% of total shares outstanding. Company insiders own approximately 19.67%, while retail and public investors account for the remaining 12.65%.
The largest institutional shareholder of Black Diamond Therapeutics, Inc. is T. ROWE PRICE INVESTMENT MANAGEMENT, INC., holding approximately 10.74 million shares — equal to 18.91% of outstanding shares — as of September 30, 2025.
A total of 90 institutional investors currently hold BDTX stock, with a combined institutional value of approximately $146,973,938 as of the most recent 13F filing period.
Frequently asked questions
BDTX ownershipBlack Diamond Therapeutics, Inc. (BDTX) is primarily owned by institutional investors, who hold approximately 67.7% of shares. The largest shareholder is T. ROWE PRICE INVESTMENT MANAGEMENT, INC. with a 18.91% stake. Company insiders hold 19.67%. Data sourced from SEC Form 13F as of September 30, 2025.